Eli Lilly and Sanofi have agreed terms in a patent dispute revolving around insulin glargine which will ward off the launch of a biosimilar to Sanofi’s Lantus brand until the end of next year. The settlement relates to patents covering Sanofi’s Lantus SoloSTAR formulation of the basal insulin, a pen injector version which accounts … Continue reading Lilly Set to Launch Lantus Biosimilar in the US Next Year
Read more
Everything you need to know
about biosimilars in one place
about biosimilars in one place
Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount
Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount Novartis’ Zarxio is the biosimilar of Amgen’s biologic, Neuopgen. It is expected the due to the fact that Zarxio will be sold at cheaper price, it will increase access to treatment. Amgen had tried to stop Zarxio from reaching the market many times, but with no avail. … Continue reading Novartis Launches First U.S. ‘Biosimilar’ Drug at 15% Discount
Read moreWhat Do Gastroenterologists Think About Biosimilars?
The American Gastroenterological Association surveyed 180 of its members on biosimilars and biologics. In late July, the American Gastroenterological Association released findings from a national survey of gastroenterologists on biosimilars and biologics. Biologics are used regularly for the treatment of inflammatory bowel disease (IBD), and biosimilars for the treatment of IBD, such as Remsima/Inflectra … Continue reading What Do Gastroenterologists Think About Biosimilars?
Read moreTrade Deal Could Effect Cost and Regulation of Biosimilars
For five years, the United States, along with 11 other countries have been negotiating the terms of the Trans- Pacific partnership, a trade deal between multiple Pacific Rim countries. In this deal, there is discussion on the pricing and regulation of drugs. Patents play a key role in the biosimilar industry. Many of the … Continue reading Trade Deal Could Effect Cost and Regulation of Biosimilars
Read moreZarxio Cleared for September Take-Off
The first U.S. biosimilar, Zarxio, should be on the market by September, after an appeals court ruled in its favour. In a move that has surprised some, Zarxio, the first FDA-approved biosimilar looks set for a September market launch after a U.S. appeals court ruled its maker had not violated any information disclosure requirements. … Continue reading Zarxio Cleared for September Take-Off
Read morePediatric Experts Caution Against Switching Kids with IBD to Biosimilars
European pediatricians say caution and long-term safety and efficacy studies are needed before switching children with IBD to biosimilars. A group of 10 pediatric specialists has published a statement calling for children with inflammatory bowel disease (IBD), who are already doing well on specific biologic medications, not to be switched to recently-approved biosimilar products. … Continue reading Pediatric Experts Caution Against Switching Kids with IBD to Biosimilars
Read moreGlobal Biosimilar Market to Reach $6.22 Million by 2020, Says Report
A new report predicts the global biosimilars market will reach $6.22 billion by 2020, and examines the drivers and impediments to its growth. According to a new market research report, the global biosimilars market will reach $6.22 billion by 2020, up from $2.29 billion in 2015, at a compound annual growth rate (CAGR) of … Continue reading Global Biosimilar Market to Reach $6.22 Million by 2020, Says Report
Read moreBiosimilar Thought Leaders Series: Duncan Emerton
BioLink is honored to kick off our Thought Leader Series with Dr. Duncan Emerton, Senior Director of Syndicated Insights and Analysis at FirstWord Pharma, and the man behind the Biosimilarz blog and on Twitter. Dr. Emerton has established himself as a thought leader in the biosimilars community, presenting at numerous biosimilar conferences, including the 4th Annual … Continue reading Biosimilar Thought Leaders Series: Duncan Emerton
Read moreThe Affordable Care Act and the Battle for Biosimilars
The passage of the Affordable Care Act (ACA) in 2010 opened up a pathway for the production and approval of biosimilar medications. Biosimilars are “copies” of complex biologic medical drugs, and are seen as cost-effective alternatives to expensive medications. So how did the regulations around biosimilars come to be? Steven Brill in his book … Continue reading The Affordable Care Act and the Battle for Biosimilars
Read moreSamsung Proving a Fierce Contender in Biosimilars Race
With the recent clinical trial success of the joint Merck/Samsung Bioepis Humira biosimilar, SB5, the drug development partners are setting their sights on European approval. As AbbVie’s blockbuster Humira nears patent expiry, Merck and Samsung Bioepis seem ready to corner the market with their version of the best-selling injectable drug, which is used to treat … Continue reading Samsung Proving a Fierce Contender in Biosimilars Race
Read more
